Loading…
Inhibin forms in serum from postmenopausal women with ovarian cancers
BACKGROUND AND OBJECTIVE Previous studies have shown that serum inhibin as measured by α subunit‐directed radioimmunoassay (RIA) and inhibin A ELISA was elevated in postmenopausal women with mucinous and granulosa cell cancers, with the RIA showing a more frequent elevation than the inhibin A ELISA....
Saved in:
| Published in: | Clinical endocrinology (Oxford) 1999-03, Vol.50 (3), p.381-386 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4586-c040103469e6156a6cc86b27e0533baf99313cc999821d1ac4a49a6dddcdcf1b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4586-c040103469e6156a6cc86b27e0533baf99313cc999821d1ac4a49a6dddcdcf1b3 |
| container_end_page | 386 |
| container_issue | 3 |
| container_start_page | 381 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 50 |
| creator | Robertson, David M. Cahir, Nicholas Burger, Henry G. Mamers, Pamela Groome, Nigel |
| description | BACKGROUND AND OBJECTIVE
Previous studies have shown that serum inhibin as measured by α subunit‐directed radioimmunoassay (RIA) and inhibin A ELISA was elevated in postmenopausal women with mucinous and granulosa cell cancers, with the RIA showing a more frequent elevation than the inhibin A ELISA. It was thus hypothesised that these cancers may also produce inhibin B or the free α subunit. The aim of the study was to identify the forms of inhibin found in a range of ovarian cancers using a range of inhibin assays with varying specificities.
DESIGN
Serum samples obtained from women with ovarian cancer were assayed by inhibin B ELISA and Pro‐αC subunit ELISA and compared with inhibin RIA and inhibin A ELISA.
PATIENTS
Blood samples were obtained from 34 postmenopausal women (>55 years) with no history of endocrine disease and from women with ovarian serous cystadenocarcinomas (n = 66), mucinous cystadenocarcinomas (n = 20), granulosa cell tumours (n = 9 − 11), miscellaneous ovarian cancers (n = 46) and non ovarian cancers (n = 23).
MEASUREMENTS
Inhibin B and inhibin Pro‐αC subunit levels were determined by ELISA and compared to values obtained by RIA and inhibin A ELISA. Cancers were discriminated from controls based on values obtained 2SD above the geometric mean of the control values.
RESULTS
Granulosa cell tumours were detected by RIA and inhibin B ELISA (100%), Pro‐αC ELISA (90%) and inhibin A ELISA (77%). Mucinous tumours were detected by RIA (70%), inhibin B ELISA (60%), Pro‐αC ELISA (55%) and inhibin A (20%). Serous tumours were detected by RIA (35%) and the other assays ( |
| doi_str_mv | 10.1046/j.1365-2265.1999.00656.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69936475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>40356125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4586-c040103469e6156a6cc86b27e0533baf99313cc999821d1ac4a49a6dddcdcf1b3</originalsourceid><addsrcrecordid>eNqNkE9v2yAYh9G0aU27fYUJTVNvdiHAayPtUkXpH7VKe-jUI8IYq2S2ySBu0m9fUkdt1dNOvIjn9wMehDAlOSUcTpY5ZSCy6RRETqWUOSEgIN9-QpPXg89oQhghGQHgB-gwxiUhRJSk-IoOUgkTKTJB88v-wVWux40PXcRpiDYMHW6C7_DKx3Vne7_SQ9Qt3vi0wRu3fsD-UQene2x0b2yI39CXRrfRft-vR-jP2fxudpFd35xfzk6vM8NFCZkhnFDCOEgLVIAGY0qopoUlgrFKN1IyyoxJHyqntKbacM2lhrquTW0aWrEjdDz2roL_N9i4Vp2Lxrat7q0fooLUALwQCfz5AVz6IfTpbYrKsigocEhQOUIm-BiDbdQquE6HJ0WJ2nlWS7XTqXY61c6zevGstin6Y98_VJ2t3wVHsQn4tQd0NLptQhLl4htXMGCCJuz3iG1ca5_--341my_SkOLZGHdxbbevcR3-KihYIdT94lwt4PbqVt5D6noGMEmm2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198771646</pqid></control><display><type>article</type><title>Inhibin forms in serum from postmenopausal women with ovarian cancers</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Robertson, David M. ; Cahir, Nicholas ; Burger, Henry G. ; Mamers, Pamela ; Groome, Nigel</creator><creatorcontrib>Robertson, David M. ; Cahir, Nicholas ; Burger, Henry G. ; Mamers, Pamela ; Groome, Nigel</creatorcontrib><description>BACKGROUND AND OBJECTIVE
Previous studies have shown that serum inhibin as measured by α subunit‐directed radioimmunoassay (RIA) and inhibin A ELISA was elevated in postmenopausal women with mucinous and granulosa cell cancers, with the RIA showing a more frequent elevation than the inhibin A ELISA. It was thus hypothesised that these cancers may also produce inhibin B or the free α subunit. The aim of the study was to identify the forms of inhibin found in a range of ovarian cancers using a range of inhibin assays with varying specificities.
DESIGN
Serum samples obtained from women with ovarian cancer were assayed by inhibin B ELISA and Pro‐αC subunit ELISA and compared with inhibin RIA and inhibin A ELISA.
PATIENTS
Blood samples were obtained from 34 postmenopausal women (>55 years) with no history of endocrine disease and from women with ovarian serous cystadenocarcinomas (n = 66), mucinous cystadenocarcinomas (n = 20), granulosa cell tumours (n = 9 − 11), miscellaneous ovarian cancers (n = 46) and non ovarian cancers (n = 23).
MEASUREMENTS
Inhibin B and inhibin Pro‐αC subunit levels were determined by ELISA and compared to values obtained by RIA and inhibin A ELISA. Cancers were discriminated from controls based on values obtained 2SD above the geometric mean of the control values.
RESULTS
Granulosa cell tumours were detected by RIA and inhibin B ELISA (100%), Pro‐αC ELISA (90%) and inhibin A ELISA (77%). Mucinous tumours were detected by RIA (70%), inhibin B ELISA (60%), Pro‐αC ELISA (55%) and inhibin A (20%). Serous tumours were detected by RIA (35%) and the other assays (<15%). Miscellaneous tumours were detected by RIA (41%) and other assays <30%.
CONCLUSIONS
Ovarian neoplasms may produce a variety of peptides related to the inhibins, including dimeric inhibin A and B. Inhibin B is detected in more ovarian cancers than inhibin A but does not discriminate as well as the α subunit directed assays. The higher discrimination index obtained with the RIA compared to the Pro‐αC ELISA suggests that assays detecting all inhibin forms containing the α subunit and not just those detecting the Pro‐αC subunit will provide the most useful detection method.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1046/j.1365-2265.1999.00656.x</identifier><identifier>PMID: 10435065</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford BSL: Blackwell Science Ltd</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Enzyme-Linked Immunosorbent Assay - methods ; Female ; Female genital diseases ; Follicle Stimulating Hormone - blood ; Granulosa Cell Tumor - blood ; Granulosa Cell Tumor - diagnosis ; Gynecology. Andrology. Obstetrics ; Humans ; Inhibins - blood ; Medical sciences ; Middle Aged ; Neoplasms, Cystic, Mucinous, and Serous - blood ; Neoplasms, Cystic, Mucinous, and Serous - diagnosis ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - diagnosis ; Peptides - blood ; Postmenopause - blood ; Predictive Value of Tests ; Prostatic Secretory Proteins ; Radioimmunoassay ; Tumors</subject><ispartof>Clinical endocrinology (Oxford), 1999-03, Vol.50 (3), p.381-386</ispartof><rights>Blackwell Science Ltd, Oxford</rights><rights>1999 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Mar 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4586-c040103469e6156a6cc86b27e0533baf99313cc999821d1ac4a49a6dddcdcf1b3</citedby><cites>FETCH-LOGICAL-c4586-c040103469e6156a6cc86b27e0533baf99313cc999821d1ac4a49a6dddcdcf1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1736351$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10435065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robertson, David M.</creatorcontrib><creatorcontrib>Cahir, Nicholas</creatorcontrib><creatorcontrib>Burger, Henry G.</creatorcontrib><creatorcontrib>Mamers, Pamela</creatorcontrib><creatorcontrib>Groome, Nigel</creatorcontrib><title>Inhibin forms in serum from postmenopausal women with ovarian cancers</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clinical Endocrinology</addtitle><description>BACKGROUND AND OBJECTIVE
Previous studies have shown that serum inhibin as measured by α subunit‐directed radioimmunoassay (RIA) and inhibin A ELISA was elevated in postmenopausal women with mucinous and granulosa cell cancers, with the RIA showing a more frequent elevation than the inhibin A ELISA. It was thus hypothesised that these cancers may also produce inhibin B or the free α subunit. The aim of the study was to identify the forms of inhibin found in a range of ovarian cancers using a range of inhibin assays with varying specificities.
DESIGN
Serum samples obtained from women with ovarian cancer were assayed by inhibin B ELISA and Pro‐αC subunit ELISA and compared with inhibin RIA and inhibin A ELISA.
PATIENTS
Blood samples were obtained from 34 postmenopausal women (>55 years) with no history of endocrine disease and from women with ovarian serous cystadenocarcinomas (n = 66), mucinous cystadenocarcinomas (n = 20), granulosa cell tumours (n = 9 − 11), miscellaneous ovarian cancers (n = 46) and non ovarian cancers (n = 23).
MEASUREMENTS
Inhibin B and inhibin Pro‐αC subunit levels were determined by ELISA and compared to values obtained by RIA and inhibin A ELISA. Cancers were discriminated from controls based on values obtained 2SD above the geometric mean of the control values.
RESULTS
Granulosa cell tumours were detected by RIA and inhibin B ELISA (100%), Pro‐αC ELISA (90%) and inhibin A ELISA (77%). Mucinous tumours were detected by RIA (70%), inhibin B ELISA (60%), Pro‐αC ELISA (55%) and inhibin A (20%). Serous tumours were detected by RIA (35%) and the other assays (<15%). Miscellaneous tumours were detected by RIA (41%) and other assays <30%.
CONCLUSIONS
Ovarian neoplasms may produce a variety of peptides related to the inhibins, including dimeric inhibin A and B. Inhibin B is detected in more ovarian cancers than inhibin A but does not discriminate as well as the α subunit directed assays. The higher discrimination index obtained with the RIA compared to the Pro‐αC ELISA suggests that assays detecting all inhibin forms containing the α subunit and not just those detecting the Pro‐αC subunit will provide the most useful detection method.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Granulosa Cell Tumor - blood</subject><subject>Granulosa Cell Tumor - diagnosis</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Inhibins - blood</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasms, Cystic, Mucinous, and Serous - blood</subject><subject>Neoplasms, Cystic, Mucinous, and Serous - diagnosis</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Peptides - blood</subject><subject>Postmenopause - blood</subject><subject>Predictive Value of Tests</subject><subject>Prostatic Secretory Proteins</subject><subject>Radioimmunoassay</subject><subject>Tumors</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqNkE9v2yAYh9G0aU27fYUJTVNvdiHAayPtUkXpH7VKe-jUI8IYq2S2ySBu0m9fUkdt1dNOvIjn9wMehDAlOSUcTpY5ZSCy6RRETqWUOSEgIN9-QpPXg89oQhghGQHgB-gwxiUhRJSk-IoOUgkTKTJB88v-wVWux40PXcRpiDYMHW6C7_DKx3Vne7_SQ9Qt3vi0wRu3fsD-UQene2x0b2yI39CXRrfRft-vR-jP2fxudpFd35xfzk6vM8NFCZkhnFDCOEgLVIAGY0qopoUlgrFKN1IyyoxJHyqntKbacM2lhrquTW0aWrEjdDz2roL_N9i4Vp2Lxrat7q0fooLUALwQCfz5AVz6IfTpbYrKsigocEhQOUIm-BiDbdQquE6HJ0WJ2nlWS7XTqXY61c6zevGstin6Y98_VJ2t3wVHsQn4tQd0NLptQhLl4htXMGCCJuz3iG1ca5_--341my_SkOLZGHdxbbevcR3-KihYIdT94lwt4PbqVt5D6noGMEmm2A</recordid><startdate>199903</startdate><enddate>199903</enddate><creator>Robertson, David M.</creator><creator>Cahir, Nicholas</creator><creator>Burger, Henry G.</creator><creator>Mamers, Pamela</creator><creator>Groome, Nigel</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>199903</creationdate><title>Inhibin forms in serum from postmenopausal women with ovarian cancers</title><author>Robertson, David M. ; Cahir, Nicholas ; Burger, Henry G. ; Mamers, Pamela ; Groome, Nigel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4586-c040103469e6156a6cc86b27e0533baf99313cc999821d1ac4a49a6dddcdcf1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Granulosa Cell Tumor - blood</topic><topic>Granulosa Cell Tumor - diagnosis</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Inhibins - blood</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasms, Cystic, Mucinous, and Serous - blood</topic><topic>Neoplasms, Cystic, Mucinous, and Serous - diagnosis</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Peptides - blood</topic><topic>Postmenopause - blood</topic><topic>Predictive Value of Tests</topic><topic>Prostatic Secretory Proteins</topic><topic>Radioimmunoassay</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robertson, David M.</creatorcontrib><creatorcontrib>Cahir, Nicholas</creatorcontrib><creatorcontrib>Burger, Henry G.</creatorcontrib><creatorcontrib>Mamers, Pamela</creatorcontrib><creatorcontrib>Groome, Nigel</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robertson, David M.</au><au>Cahir, Nicholas</au><au>Burger, Henry G.</au><au>Mamers, Pamela</au><au>Groome, Nigel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibin forms in serum from postmenopausal women with ovarian cancers</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clinical Endocrinology</addtitle><date>1999-03</date><risdate>1999</risdate><volume>50</volume><issue>3</issue><spage>381</spage><epage>386</epage><pages>381-386</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>BACKGROUND AND OBJECTIVE
Previous studies have shown that serum inhibin as measured by α subunit‐directed radioimmunoassay (RIA) and inhibin A ELISA was elevated in postmenopausal women with mucinous and granulosa cell cancers, with the RIA showing a more frequent elevation than the inhibin A ELISA. It was thus hypothesised that these cancers may also produce inhibin B or the free α subunit. The aim of the study was to identify the forms of inhibin found in a range of ovarian cancers using a range of inhibin assays with varying specificities.
DESIGN
Serum samples obtained from women with ovarian cancer were assayed by inhibin B ELISA and Pro‐αC subunit ELISA and compared with inhibin RIA and inhibin A ELISA.
PATIENTS
Blood samples were obtained from 34 postmenopausal women (>55 years) with no history of endocrine disease and from women with ovarian serous cystadenocarcinomas (n = 66), mucinous cystadenocarcinomas (n = 20), granulosa cell tumours (n = 9 − 11), miscellaneous ovarian cancers (n = 46) and non ovarian cancers (n = 23).
MEASUREMENTS
Inhibin B and inhibin Pro‐αC subunit levels were determined by ELISA and compared to values obtained by RIA and inhibin A ELISA. Cancers were discriminated from controls based on values obtained 2SD above the geometric mean of the control values.
RESULTS
Granulosa cell tumours were detected by RIA and inhibin B ELISA (100%), Pro‐αC ELISA (90%) and inhibin A ELISA (77%). Mucinous tumours were detected by RIA (70%), inhibin B ELISA (60%), Pro‐αC ELISA (55%) and inhibin A (20%). Serous tumours were detected by RIA (35%) and the other assays (<15%). Miscellaneous tumours were detected by RIA (41%) and other assays <30%.
CONCLUSIONS
Ovarian neoplasms may produce a variety of peptides related to the inhibins, including dimeric inhibin A and B. Inhibin B is detected in more ovarian cancers than inhibin A but does not discriminate as well as the α subunit directed assays. The higher discrimination index obtained with the RIA compared to the Pro‐αC ELISA suggests that assays detecting all inhibin forms containing the α subunit and not just those detecting the Pro‐αC subunit will provide the most useful detection method.</abstract><cop>Oxford BSL</cop><pub>Blackwell Science Ltd</pub><pmid>10435065</pmid><doi>10.1046/j.1365-2265.1999.00656.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 1999-03, Vol.50 (3), p.381-386 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69936475 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Aged Aged, 80 and over Biological and medical sciences Enzyme-Linked Immunosorbent Assay - methods Female Female genital diseases Follicle Stimulating Hormone - blood Granulosa Cell Tumor - blood Granulosa Cell Tumor - diagnosis Gynecology. Andrology. Obstetrics Humans Inhibins - blood Medical sciences Middle Aged Neoplasms, Cystic, Mucinous, and Serous - blood Neoplasms, Cystic, Mucinous, and Serous - diagnosis Ovarian Neoplasms - blood Ovarian Neoplasms - diagnosis Peptides - blood Postmenopause - blood Predictive Value of Tests Prostatic Secretory Proteins Radioimmunoassay Tumors |
| title | Inhibin forms in serum from postmenopausal women with ovarian cancers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A01%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibin%20forms%20in%20serum%20from%20postmenopausal%20women%20with%20ovarian%20cancers&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Robertson,%20David%20M.&rft.date=1999-03&rft.volume=50&rft.issue=3&rft.spage=381&rft.epage=386&rft.pages=381-386&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1046/j.1365-2265.1999.00656.x&rft_dat=%3Cproquest_cross%3E40356125%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4586-c040103469e6156a6cc86b27e0533baf99313cc999821d1ac4a49a6dddcdcf1b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=198771646&rft_id=info:pmid/10435065&rfr_iscdi=true |